Illinois Medicaid covers GLP-1 medications only when they are prescribed for type 2 diabetes, and even then coverage depends on the specific drug, prior authorization, and step-therapy rules. Weight loss is an excluded benefit across the state’s fee-for-service program and its managed care organizations, so drugs like Wegovy, Zepbound, and Saxenda are not available to Medicaid enrollees for obesity treatment.1Formulary Navigator. Molina Healthcare of Illinois Medicaid PDL Formulary2GLP1 Clinics. GLP-1 Insurance Coverage
Which GLP-1s Are Covered for Type 2 Diabetes
The Illinois Medicaid Preferred Drug List, updated in March 2025, sorts GLP-1 receptor agonists into three tiers under “Antidiabetics: Incretin Mimetic Agents”:3Illinois HFS. Illinois Medicaid Preferred Drug List
- Preferred: generic liraglutide, Victoza, and Trulicity
- Preferred with prior authorization: Rybelsus (oral semaglutide)
- Non-preferred: Ozempic, Mounjaro, Bydureon BCise, and Byetta
Wegovy and Zepbound do not appear on the preferred drug list, matching their weight-management indications.4Illinois HFS. Illinois Medicaid Preferred Drug List
What You Have to Show to Get Approval
Even a preferred drug requires prior authorization. Meridian’s clinical policy, which reflects the broader state framework, sets out the criteria a prescriber must document:5IL Meridian. GLP-1 Receptor Agonists Clinical Policy
- Diagnosis of type 2 diabetes. Any other indication is denied.
- HbA1c of 7% or higher within the past three months.
- Age 18 or older for most GLP-1s. Trulicity, Victoza, and Bydureon BCise are available to patients 10 and older.
- For Rybelsus: at least three consecutive months on the maximum tolerated dose of metformin, unless metformin is contraindicated.
- For non-preferred drugs: documented failure over three consecutive months on two preferred GLP-1s (Rybelsus, Trulicity, or Victoza).
- For Ozempic in patients with cardiovascular disease or risk factors: failure of three consecutive months on both Trulicity and Victoza.
- No concurrent use of two GLP-1 receptor agonists.
In practice, a Medicaid enrollee with type 2 diabetes who wants Ozempic or Mounjaro will usually have to try and fail on cheaper GLP-1s first.
Why Weight-Loss Prescriptions Are Denied
Federal Medicaid law lets states exclude weight-loss drugs, and Illinois takes that option. The Department of Healthcare and Family Services classifies anorectic and appetite-suppressant medications as non-covered.1Formulary Navigator. Molina Healthcare of Illinois Medicaid PDL Formulary The exclusion applies uniformly across managed care plans. Meridian’s policy says weight loss “is a benefit exclusion and is not a covered benefit,” and instructs that a request citing obesity or weight loss as the diagnosis “should be denied.”5IL Meridian. GLP-1 Receptor Agonists Clinical Policy Molina’s 2026 preferred drug list lists “Appetite Suppressants / Anorexiants for weight loss” among non-covered categories.
The exclusion targets the indication, not the molecule. That distinction matters because it opens a narrow door.
The Wegovy Cardiovascular Exception
After the FDA approved semaglutide to reduce the risk of major cardiovascular events in adults with established heart disease and obesity or overweight, at least one Illinois Medicaid managed care plan built a coverage pathway around that indication. Aetna Better Health of Illinois, in a policy effective September 2025, authorizes Wegovy for cardiovascular risk reduction when the patient meets all of the following: a history of heart attack, stroke, peripheral arterial disease, or prior cardiac revascularization; a baseline BMI of 27 or higher; no type 2 diabetes diagnosis (patients with diabetes are directed to Ozempic instead); and current treatment with standard cardiovascular therapies.6Aetna Better Health. Wegovy Cardiovascular Aetna IL Medicaid Policy
The policy is blunt that “use of Wegovy for the indication of weight loss only is an excluded benefit and will not be covered.” Initial approval runs for seven months, with 12-month renewals available. If you are on a different managed care plan, check its own clinical policy before assuming the same pathway exists.
State Employees Have Coverage. Medicaid Enrollees Do Not.
It is worth naming a source of confusion. Illinois passed a law requiring health plans in the State Employees Group Insurance Program to cover medically necessary injectable medications prescribed for glucose improvement or weight loss. Governor JB Pritzker signed it in June 2023, and the requirement took effect July 1, 2024.7Illinois General Assembly. 5 ILCS 375/6.11C8Becker’s Payer. Illinois Expands Weight Loss Drug Coverage to State Employees9Illinois CMS. Summary of Benefits and Coverage
That law does not extend to Medicaid enrollees or to state retirees on Medicare Advantage plans.8Becker’s Payer. Illinois Expands Weight Loss Drug Coverage to State Employees News coverage about Illinois paying for weight-loss drugs refers to the state employee benefit, which is a separate program from Medicaid.
What Could Change
The federal BALANCE model, launched by the Centers for Medicare and Medicaid Services in late 2025, is a voluntary five-year demonstration designed to lower GLP-1 prices and expand coverage to Medicare and Medicaid beneficiaries. State Medicaid agencies can opt in beginning May 2026, with an application deadline of July 31, 2026. Novo Nordisk and Eli Lilly have agreed to participate; the negotiated Medicare price is $245 per 30-day supply, and Medicaid pricing is confidential.10CMS. BALANCE Model11KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
Covered drugs would include all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen formulation of Zepbound, and Orforglipron if the FDA approves it. Eligibility requires BMI thresholds combined with comorbid conditions such as heart failure, uncontrolled hypertension, chronic kidney disease, obstructive sleep apnea, or noncirrhotic liver fibrosis, and manufacturers must fund no-cost lifestyle support programs.10CMS. BALANCE Model
Illinois is eligible to apply as a participant in the Medicaid Drug Rebate Program. Whether the state will opt in had not been publicly announced as of early 2026.